AngioDynamics, Inc. (ANGO)
USD 8.93
(-3.56%)
USD 8.93
(-3.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 303.91 Million USD | -10.28% |
| 2023 | 338.75 Million USD | 7.13% |
| 2022 | 316.21 Million USD | 8.66% |
| 2021 | 291.01 Million USD | 10.17% |
| 2020 | 264.15 Million USD | -26.52% |
| 2019 | 359.48 Million USD | 4.41% |
| 2018 | 344.28 Million USD | -1.53% |
| 2017 | 349.64 Million USD | -1.14% |
| 2016 | 353.69 Million USD | -0.92% |
| 2015 | 356.97 Million USD | 0.71% |
| 2014 | 354.45 Million USD | 3.63% |
| 2013 | 342.02 Million USD | 54.21% |
| 2012 | 221.78 Million USD | 2.7% |
| 2011 | 215.95 Million USD | -0.04% |
| 2010 | 216.03 Million USD | 10.76% |
| 2009 | 195.05 Million USD | 17.15% |
| 2008 | 166.5 Million USD | 48.36% |
| 2007 | 112.22 Million USD | 43.05% |
| 2006 | 78.45 Million USD | 30.12% |
| 2005 | 60.28 Million USD | 22.9% |
| 2004 | 49.05 Million USD | 27.63% |
| 2003 | 38.43 Million USD | 24.42% |
| 2002 | 30.89 Million USD | 32.06% |
| 2001 | 23.39 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 78.67 Million USD | -13.61% |
| 2024 Q3 | 75.18 Million USD | -4.92% |
| 2024 FY | 303.91 Million USD | -10.28% |
| 2024 Q4 | 70.98 Million USD | -5.59% |
| 2024 Q2 | 79.07 Million USD | 0.5% |
| 2023 Q1 | 81.53 Million USD | -6.28% |
| 2023 Q2 | 85.42 Million USD | 4.77% |
| 2023 Q3 | 80.71 Million USD | -5.52% |
| 2023 Q4 | 91.07 Million USD | 12.84% |
| 2023 FY | 338.75 Million USD | 7.13% |
| 2022 FY | 316.21 Million USD | 8.66% |
| 2022 Q4 | 86.99 Million USD | 17.61% |
| 2022 Q3 | 73.97 Million USD | -5.51% |
| 2022 Q2 | 78.28 Million USD | 1.7% |
| 2022 Q1 | 76.97 Million USD | 0.17% |
| 2021 Q4 | 76.84 Million USD | 7.95% |
| 2021 Q3 | 71.18 Million USD | -2.18% |
| 2021 FY | 291.01 Million USD | 10.17% |
| 2021 Q2 | 72.77 Million USD | 3.64% |
| 2021 Q1 | 70.21 Million USD | 20.37% |
| 2020 FY | 264.15 Million USD | -26.52% |
| 2020 Q4 | 58.33 Million USD | -16.41% |
| 2020 Q3 | 69.78 Million USD | -0.32% |
| 2020 Q2 | 70 Million USD | 6.0% |
| 2020 Q1 | 66.04 Million USD | -31.42% |
| 2019 Q2 | 91.5 Million USD | 7.22% |
| 2019 FY | 359.48 Million USD | 4.41% |
| 2019 Q1 | 85.34 Million USD | -3.37% |
| 2019 Q4 | 96.3 Million USD | 11.53% |
| 2019 Q3 | 86.34 Million USD | -5.64% |
| 2018 Q2 | 86.7 Million USD | 1.52% |
| 2018 Q1 | 85.41 Million USD | -1.73% |
| 2018 FY | 344.28 Million USD | -1.53% |
| 2018 Q4 | 88.31 Million USD | 5.33% |
| 2018 Q3 | 83.85 Million USD | -3.29% |
| 2017 FY | 349.64 Million USD | -1.14% |
| 2017 Q2 | 89.02 Million USD | 1.06% |
| 2017 Q3 | 85.6 Million USD | -3.85% |
| 2017 Q4 | 86.91 Million USD | 1.53% |
| 2017 Q1 | 88.09 Million USD | -5.65% |
| 2016 Q3 | 87.38 Million USD | -2.07% |
| 2016 Q1 | 83.7 Million USD | -7.91% |
| 2016 FY | 353.69 Million USD | -0.92% |
| 2016 Q2 | 89.23 Million USD | 6.61% |
| 2016 Q4 | 93.36 Million USD | 6.85% |
| 2015 FY | 356.97 Million USD | 0.71% |
| 2015 Q1 | 87.33 Million USD | -7.16% |
| 2015 Q4 | 90.89 Million USD | 4.97% |
| 2015 Q3 | 86.59 Million USD | -6.03% |
| 2015 Q2 | 92.14 Million USD | 5.52% |
| 2014 Q3 | 88.19 Million USD | -0.48% |
| 2014 Q1 | 83.57 Million USD | -7.17% |
| 2014 Q4 | 94.06 Million USD | 6.66% |
| 2014 Q2 | 88.61 Million USD | 6.03% |
| 2014 FY | 354.45 Million USD | 3.63% |
| 2013 Q1 | 83.4 Million USD | 44.58% |
| 2013 FY | 342.02 Million USD | 54.21% |
| 2013 Q4 | 90.03 Million USD | 10.37% |
| 2013 Q3 | 81.57 Million USD | -6.25% |
| 2013 Q2 | 87 Million USD | 4.32% |
| 2012 Q1 | 54.43 Million USD | -3.54% |
| 2012 FY | 221.78 Million USD | 2.7% |
| 2012 Q4 | 57.69 Million USD | 11.87% |
| 2012 Q3 | 51.56 Million USD | -11.24% |
| 2012 Q2 | 58.09 Million USD | 6.74% |
| 2011 Q2 | 53.37 Million USD | 3.62% |
| 2011 FY | 215.95 Million USD | -0.04% |
| 2011 Q4 | 56.43 Million USD | 3.26% |
| 2011 Q1 | 51.5 Million USD | -14.55% |
| 2011 Q3 | 54.64 Million USD | 2.39% |
| 2010 Q4 | 60.27 Million USD | 15.46% |
| 2010 FY | 216.03 Million USD | 10.76% |
| 2010 Q3 | 52.2 Million USD | -2.34% |
| 2010 Q1 | 50.09 Million USD | -5.16% |
| 2010 Q2 | 53.45 Million USD | 6.72% |
| 2009 FY | 195.05 Million USD | 17.15% |
| 2009 Q1 | 44.32 Million USD | -5.2% |
| 2009 Q4 | 52.82 Million USD | 6.82% |
| 2009 Q3 | 49.44 Million USD | 2.03% |
| 2009 Q2 | 48.46 Million USD | 9.34% |
| 2008 Q2 | 41.49 Million USD | 10.58% |
| 2008 FY | 166.5 Million USD | 48.36% |
| 2008 Q3 | 40.72 Million USD | -1.86% |
| 2008 Q1 | 37.52 Million USD | -8.15% |
| 2008 Q4 | 46.75 Million USD | 14.8% |
| 2007 Q3 | 26.73 Million USD | 9.72% |
| 2007 FY | 112.22 Million USD | 43.05% |
| 2007 Q2 | 24.36 Million USD | 20.25% |
| 2007 Q4 | 40.85 Million USD | 52.8% |
| 2007 Q1 | 20.26 Million USD | -14.1% |
| 2006 Q2 | 18.7 Million USD | 14.3% |
| 2006 Q4 | 23.59 Million USD | 19.24% |
| 2006 Q3 | 19.78 Million USD | 5.76% |
| 2006 Q1 | 16.36 Million USD | -5.57% |
| 2006 FY | 78.45 Million USD | 30.12% |
| 2005 Q4 | 17.33 Million USD | 12.18% |
| 2005 FY | 60.28 Million USD | 22.9% |
| 2005 Q3 | 15.45 Million USD | 7.28% |
| 2005 Q1 | 13.1 Million USD | -7.18% |
| 2005 Q2 | 14.4 Million USD | 9.9% |
| 2004 Q3 | 11.64 Million USD | 0.0% |
| 2004 Q4 | 14.11 Million USD | 21.25% |
| 2004 FY | 49.05 Million USD | 27.63% |
| 2003 FY | 38.43 Million USD | 24.42% |
| 2003 Q4 | 11.23 Million USD | 65.22% |
| 2003 Q3 | 6.8 Million USD | 0.0% |
| 2002 FY | 30.89 Million USD | 32.06% |
| 2001 FY | 23.39 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 96.63 Million USD | -214.503% |
| AtriCure, Inc. | 399.24 Million USD | 23.878% |
| Avinger, Inc. | 7.65 Million USD | -3871.694% |
| Azenta, Inc. | 665.07 Million USD | 54.304% |
| BioLife Solutions, Inc. | 143.27 Million USD | -112.125% |
| The Cooper Companies, Inc. | 3.59 Billion USD | 91.542% |
| Daxor Corporation | 1.28 Million USD | -23633.732% |
| Ekso Bionics Holdings, Inc. | 18.27 Million USD | -1562.64% |
| Femasys Inc. | 1.07 Million USD | -28250.98% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 112.25 Million USD | -170.747% |
| Hologic, Inc. | 4.03 Billion USD | 92.459% |
| ICU Medical, Inc. | 2.25 Billion USD | 86.547% |
| Intuitive Surgical, Inc. | 7.12 Billion USD | 95.734% |
| KORU Medical Systems, Inc. | 28.51 Million USD | -965.704% |
| LeMaitre Vascular, Inc. | 193.48 Million USD | -57.074% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -26270.459% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -26270.459% |
| Masimo Corporation | 2.04 Billion USD | 85.161% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 97.09 Million USD | -212.994% |
| Merit Medical Systems, Inc. | 1.25 Billion USD | 75.829% |
| Nephros, Inc. | 14.23 Million USD | -2034.527% |
| NovoCure Limited | 509.33 Million USD | 40.332% |
| NEXGEL, Inc. | 4.08 Million USD | -7332.477% |
| NEXGEL, Inc. | 4.08 Million USD | -7332.477% |
| Singular Genomics Systems, Inc. | 2.91 Million USD | -10340.192% |
| OraSure Technologies, Inc. | 405.47 Million USD | 25.047% |
| Pro-Dex, Inc. | 53.84 Million USD | -464.434% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 1.78 Million USD | -16972.928% |
| Precision Optics Corporation, Inc. | 19.1 Million USD | -1490.81% |
| QuidelOrtho Corporation | 2.99 Billion USD | 89.862% |
| Repligen Corporation | 638.76 Million USD | 52.422% |
| Sanara MedTech Inc. | 64.98 Million USD | -367.633% |
| STAAR Surgical Company | 322.41 Million USD | 5.738% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 50.22 Million USD | -505.117% |
| DENTSPLY SIRONA Inc. | 3.96 Billion USD | 92.335% |
| Jin Medical International Ltd. | 19.82 Million USD | -1433.258% |